Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: A community-based follow-up study

Gastroenterology

Volumn 139, Issue 2, 2010, Pages 474-482

  Liu, Jessica ^a,b   Yang, Hwai I ^b   Lee, Mei Hsuan ^b,c   Lu, Sheng Nan ^d   Jen, Chin Lan ^b   Wang, Li Yu ^e   You, San Lin ^b   Iloeje, Uchenna H ^f   Chen, Chien Jen ^b,c  

^a EMORY UNIVERSITY   (United States)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e MACKAY MEDICAL COLLEGE   (Taiwan)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

Determinants; Incidence; Spontaneous HBsAg Seroclearance

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; VIRUS DNA; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEROPREVALENCE; VIRUS LOAD; AGE; AGED; BLOOD; GENETICS; HEALTH SURVEY; IMMUNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SEX DIFFERENCE; TAIWAN; TIME;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEROLOGIC TESTS; SEX FACTORS; TAIWAN; TIME FACTORS; VIRAL LOAD;

EID: 77955483993     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.04.048     Document Type: Article

References (37)

1. C.J. Chen, L.Y. Wang, and M.W. Yu Epidemiology of hepatitis B virus infection in the Asia-Pacific region J Gastroenterol Hepatol 15 Suppl 2000 E3 E6
2. M.F. Sorrell, E.A. Belongia, J. Costa, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B Ann Intern Med 150 2009 104 110
3. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
4. C.M. Chu Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma J Gastroenterol Hepatol 15 Suppl 2000 E25 E30
5. World Health Organization Hepatitis B Fact Sheet N204 2008 World Health Organization Geneva, Switzerland
6. M.F. Yuen, and C.L. Lai Natural history of chronic hepatitis B virus infection J Gastroenterol Hepatol 15 Suppl 2000 E20 E24
7. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 34 2001 1225 1241
8. W.M. Lee Hepatitis B virus infection N Engl J Med 337 1997 1733 1745
9. Y.F. Liaw, and C.M. Chu Hepatitis B virus infection Lancet 373 2009 582 592
10. C.J. Chen, U.H. Iloeje, and H.I. Yang Long-term outcomes in hepatitis B: the REVEAL-HBV study Clin Liver Dis 11 2007 797 816 viii
11. C.J. Chen, M.W. Yu, and Y.F. Liaw Epidemiological characteristics and risk factors of hepatocellular carcinoma J Gastroenterol Hepatol 12 1997 S294 S308
12. C.M. Chu, and Y.F. Liaw Hepatitis B virus-related cirrhosis: natural history and treatment Semin Liver Dis 26 2006 142 152
13. Y. Arase, K. Ikeda, F. Suzuki, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B Am J Med 119 2006 71.e9 71.e16
14. S.H. Ahn, Y.N. Park, J.Y. Park, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance J Hepatol 42 2005 188 194
15. Y.C. Chen, I.S. Sheen, C.M. Chu, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection Gastroenterology 123 2002 1084 1089
16. T.A. Shamliyan, R. MacDonald, A. Shaukat, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference Ann Intern Med 150 2009 111 124
17. O. Borgniet, P. Parvaz, C. Bouix, et al. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B J Med Virol 81 2009 1336 1342
18. W.D. Carey The prevalence and natural history of hepatitis B in the 21st century Cleve Clin J Med 76 Suppl 3 2009 S2 S5
19. H.J. Flink, M. van Zonneveld, B.E. Hansen, et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype Am J Gastroenterol 101 2006 297 303
20. M.F. Yuen, C.K. Hui, C.C. Cheng, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 2001 139 145
21. C.M. Chu, and Y.F. Liaw HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up Hepatology 45 2007 1187 1192
22. Y.F. Liaw, I.S. Sheen, T.J. Chen, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study Hepatology 13 1991 627 631
23. B.J. McMahon, P. Holck, L. Bulkow, et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus Ann Intern Med 135 2001 759 768
24. J.H. Kim, J.H. Lee, S.J. Park, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study Hepatogastroenterology 55 2008 578 581
25. J. Simonetti, L. Bulkow, B.J. McMahon, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus Hepatology 51 2010 1531 1537
26. M.F. Yuen, D.K. Wong, E. Sablon, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects Hepatology 39 2004 1694 1701
27. C.J. Chen, H.I. Yang, J. Su, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
28. WHO Expert Consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet 363 2004 157 163
29. C.J. Chen, H.I. Yang, and U.H. Iloeje Hepatitis B virus DNA levels and outcomes in chronic hepatitis B Hepatology 49 2009 S72 S84
30. D.T. Lau, J. Everhart, D.E. Kleiner, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa Gastroenterology 113 1997 1660 1667
31. R.G. Gish Hepatitis B treatment: current best practices, avoiding resistance Cleve Clin J Med 76 Suppl 3 2009 S14 S19
32. M.F. Yuen, D.K. Wong, H.J. Yuan, et al. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection J Clin Microbiol 42 2004 4882 4884
33. R.N. Chien, and Y.F. Liaw Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success Best Pract Res Clin Gastroenterol 22 2008 1081 1092
34. K.M. Flegal, M.D. Carroll, R.J. Kuczmarski, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994 Int J Obes Relat Metab Disord 22 1998 39 47
35. M.W. Yu, W.L. Shih, C.L. Lin, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men J Clin Oncol 26 2008 5576 5582
36. C.M. Chu, D.Y. Lin, and Y.F. Liaw Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond) 31 2007 871 875
37. C.F. Wu, M.W. Yu, C.L. Lin, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men Carcinogenesis 29 2008 106 112